BAY 61-3606, CDKi, and Sodium Butyrate Treatments Modulate p53 Protein Level and Its Site-Specific Phosphorylation in Human Vestibular Schwannomas In Vitro

Figure 2

(a) Western blot showing level of total and phospho p53 proteins at 24, 48, and 72 hours after treatments. The sample used is from VS4 (26 years of age). U, untreated; B, Na-Bu; C, CDKi; S, BAY 61-3606, . (b) Western blot analysis of level of total and phospho p53 proteins at 24, 48, and 72 hours after treatment. This data is from sample number VS17 (55 years of age). U, untreated, B, Na-Bu, C, CDKi, S, BAY 61-3606, . (c) Histogram indicating level of total p53 protein at 24, 48, and 72 hours after treatment. This is data from sample VS4 (26 years) sample. UT, untreated; the treatments are as indicated in the figure, . (d) Histogram indicating level of phospho Ser392 p53 protein after treatment at various time points. This data is from VS4 (26 years old) sample. UT, untreated; the treatments are as indicated. Basal level of Ser392 p53 protein was found in older patients of above 35 years of age and it remained unchanged with all the three treatments, . (e) Level of Ser15 p53 protein at various time points after treatment. This data is from VS17 (26 years old). UT, untreated; other treatments are as shown in the figure. (f) Level of Ser315 protein after treatment at various time points. This data is from VS17 (55 years old). UT, untreated; the other treatments are shown in figure. Basal level of Ser315 p53 protein was found in young VS patients and the level remained unchanged upon all the three treatments.

(a)

(b)

(c)

(d)

(e)

(f)